2ND-Line Therapies After 1st-Line Therapy with Folfiri in Combination with Cetuximab or Bevacizumab in Patients with KRAS Wild-Type Metastatic Colorectal Cancer (MCRC)-Analysis of the AIO KRK 0306 (FIRE 3)- Trial
Open Access
- 1 June 2014
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 25, ii112